← Back to all trials
Terminated
NCT06640569
Preliminary Characterization of Commercial Kratom Extract Products
Conditions: Kratom Pharmacodynamics, Kratom Pharmacokinetics
Sex: All
Ages: 21 Years – N/A
Healthy volunteers: Yes
Enrollment: 2
Sponsor: Johns Hopkins University
Location: Johns Hopkins University Behavioral Pharmacology Research Unit Baltimore Maryland
Summary
To understand the acute subjective, physiological, and cognitive effects of commercial kratom extract products among US adults who consume these products regularly, and to understand how these products are metabolized by the human body.
Eligibility Criteria
Inclusion Criteria:
* 1\) \>21 years old;
* 2\) Experienced kratom extract product consumer of one of the leading US brands listed in the study protocol;
* 3\) Reports a specific kratom extract product brand and specific dose amount (or range of typical dose amount) on the online screener;
* 4\) English language proficient;
* 5\) Willingness to provide requested samples of the kratom extract product currently being taken.
Exclusion Criteria:
* 1\) Reports any acute adverse or unexpected or otherwise sudden health event related to their typical kratom product dose that occurred within 30 days of screening;
* 2\) Having ever sought medical attention for an acute adverse health event as a result of taking any kratom product;
* 3\) Cannot or will not provide their kratom extract product samples in the form of an unopened package that is clearly labeled with at least the product and vendor name;
* 4)The kratom extract product used by the participant has any semi-synthetic or fully synthetic ingredient listed or is known by the study team to have such an ingredient;
* 5\) Currently breastfeeding or pregnant;
* 6\) history or current diagnosis of psychotic disorder;
* 7\) current untreated bipolar disorder; 8) current untreated major depressive disorder;
* 8\) Current physical dependence on alcohol, benzodiazepines, or opioids (self-reported or otherwise evidenced) requiring medical intervention;
* 9\) Reports use of fentanyl within the past month and/or has a fentanyl positive drug screen;
* 10\) Discordance between self-reported substance use and drug screen results obtained during screening;
* 11)Any physical, psychiatric, environmental, situational, or kratom product-related condition considered by the study team to increase risk or undue burden.
Source: ClinicalTrials.gov (NCT06640569). StuddyBuddy aggregates publicly available trial information.
